Abstract | BACKGROUND: METHODS: The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG-asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l- asparaginase activity and formation of anti- PEG-asparaginase antibodies. A total of 97 evaluable patients (1-17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG-asparaginase (Oncaspar® ) 1,000 IU/m²/dose, at 2-week or 6-week intervals with a total of 30-week treatment (Clinical trials.gov. no.: NCT00819351). RESULTS: CONCLUSION:
|
Authors | Louise Tram Henriksen, Sofie Gottschalk Højfeldt, Kjeld Schmiegelow, Thomas Leth Frandsen, Peder Skov Wehner, Henrik Schrøder, Birgitte Klug Albertsen, Nordic Society of Pediatric Hematology and Oncology, NOPHO Group |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 64
Issue 12
(Dec 2017)
ISSN: 1545-5017 [Electronic] United States |
PMID | 28660740
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2017 Wiley Periodicals, Inc. |
Chemical References |
- Antibodies
- Antineoplastic Agents
- Polyethylene Glycols
- pegaspargase
- Asparaginase
|
Topics |
- Adolescent
- Antibodies
(blood)
- Antineoplastic Agents
(therapeutic use)
- Asparaginase
(blood, immunology, pharmacokinetics, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Infant
- Male
- Polyethylene Glycols
(pharmacokinetics, therapeutic use)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(blood, drug therapy)
|